New York, June 9, 2026, 09:02 (EDT)
Regentis Biomaterials shares were quoted at $1.28 before the New York open on Tuesday, down 2 cents from their previous close, after the Israeli regenerative-medicine company set out the next step in its European launch plan for GelrinC, its knee cartilage repair implant.
The move was not big. The timing was. Regentis said it plans to start European surgeon training in the third quarter, a practical bridge between regulatory clearance and commercial use for a device company still trying to prove it can turn clinical data into sales.
The stock remains a long way from its December initial public offering price of $8 a share. Regentis raised $10 million in that IPO and said proceeds would help fund its pivotal trial and preparation of a U.S. premarket approval, or PMA, submission — the FDA review route used for higher-risk medical devices.
Regentis said the first hands-on training is expected to take place at Humanitas Research Hospital in Milan, with more sessions planned in other European markets. The company said the program is meant to give orthopedic surgeons practical experience with GelrinC before a broader rollout.
GelrinC is a hydrogel implant, meaning a water-rich polymer material, designed to be placed in the knee and resorbed as surrounding cells regenerate cartilage. Regentis says the product has CE Mark approval in Europe, a conformity mark that allows sale of certain medical devices in the European market, while its U.S. study remains under way.
“The initiation of surgeon training activities represents an important commercial milestone,” Regentis Chief Executive Dr. Ehud Geller said in the company’s release, calling physician training a “critical next step” for adoption.
The Milan link also gives Regentis a named clinical champion in Europe. In April, Prof. Elizaveta Kon of Humanitas said there was a “clear need” for cartilage repair options that are biologically effective and practical in daily clinical use. ACCESS Newswire
The competitive backdrop is not empty. Smith+Nephew markets CARTIHEAL AGILI-C, an FDA-approved cartilage repair implant, and said in April that new five-year data showed stronger pain relief and functional gains versus surgical standard of care. Vericel’s MACI, an autologous product — made using a patient’s own cells — is also FDA-approved for symptomatic full-thickness cartilage defects of the knee in adults.
That matters for Regentis because “off-the-shelf” is one of its central claims: the product is not custom-grown from a patient biopsy. It may help simplify use, but it does not by itself answer questions on reimbursement, repeat surgeon demand or U.S. approval.
But the risks are plain. Regentis’ own forward-looking language points to uncertainty around clinical-trial results, FDA approval, market acceptance by doctors and payers, competing therapies and the need for capital. A small medtech stock can move fast on launch headlines; it can fall just as quickly if training does not translate into orders or if U.S. trial timing slips.
For now, Tuesday’s tape is a narrow test. Investors have a fresh commercial milestone, not revenue proof.
